BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu J, Chen J, Li W, Lian W, Huang J, Lai B, Li L, Huang Z. Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus. J Am Soc Nephrol 2020;31:54-65. [PMID: 31604808 DOI: 10.1681/ASN.2019050545] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Qin Y, Ren S, Shao B, Qin H, Wang H, Li G, Zhu Y, Sun C, Li C, Zhang J, Wang H. The intellectual base and research fronts of IL-37: A bibliometric review of the literature from WoSCC. Front Immunol 2022;13:931783. [DOI: 10.3389/fimmu.2022.931783] [Reference Citation Analysis]
2 Li A, Guo F, Pan Q, Chen S, Chen J, Liu HF, Pan Q. Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus. Front Immunol 2021;12:728190. [PMID: 34659214 DOI: 10.3389/fimmu.2021.728190] [Reference Citation Analysis]
3 Zhang Q, Xu Y, Xu J. Editorial: Targeting Heterogeneity of Mesenchymal Stem Cells. Front Cell Dev Biol 2022;10:894008. [DOI: 10.3389/fcell.2022.894008] [Reference Citation Analysis]
4 El-Jawhari JJ, El-Sherbiny Y, McGonagle D, Jones E. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors? Front Immunol 2021;12:643170. [PMID: 33732263 DOI: 10.3389/fimmu.2021.643170] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Han MM, Yuan XR, Shi X, Zhu XY, Su Y, Xiong DK, Zhang XM, Zhou H, Wang JN. The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases. Front Pharmacol 2021;12:732790. [PMID: 34539413 DOI: 10.3389/fphar.2021.732790] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tang TT, Wang B, Lv LL, Dong Z, Liu BC. Extracellular vesicles for renal therapeutics: State of the art and future perspective. J Control Release 2022:S0168-3659(22)00391-1. [PMID: 35779658 DOI: 10.1016/j.jconrel.2022.06.049] [Reference Citation Analysis]
7 Xu W, Huang Q, Yang C, Li R, Huang A. GDF-15: A Potential Biomarker and Therapeutic Target in Systemic Lupus Erythematosus. Front Immunol 2022;13:926373. [DOI: 10.3389/fimmu.2022.926373] [Reference Citation Analysis]
8 Nold-Petry CA, Nold MF. Rationale for IL-37 as a novel therapeutic agent in inflammation. Expert Rev Clin Immunol 2022. [PMID: 35916240 DOI: 10.1080/1744666X.2022.2108792] [Reference Citation Analysis]
9 Abdelgawad M, Bakry NS, Farghali AA, Abdel-Latif A, Lotfy A. Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects. Stem Cell Res Ther 2021;12:469. [PMID: 34419143 DOI: 10.1186/s13287-021-02542-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Su Z, Tao X. Current Understanding of IL-37 in Human Health and Disease. Front Immunol 2021;12:696605. [PMID: 34248996 DOI: 10.3389/fimmu.2021.696605] [Reference Citation Analysis]
11 Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M. Stem cell therapy for COVID-19 pneumonia. Mol Biomed 2022;3:6. [PMID: 35174448 DOI: 10.1186/s43556-021-00067-8] [Reference Citation Analysis]
12 Qin H, Sun C, Zhu Y, Qin Y, Ren S, Wang Z, Li C, Li X, Zhang B, Hao J, Li G, Wang H, Shao B, Zhang J, Wang H. IL-37 overexpression promotes endometrial regenerative cell-mediated inhibition of cardiac allograft rejection. Stem Cell Res Ther 2022;13:302. [PMID: 35841010 DOI: 10.1186/s13287-022-02982-1] [Reference Citation Analysis]
13 Jiang Z, Fu M, Zhu D, Wang X, Li N, Ren L, He J, Yang G. Genetically modified immunomodulatory cell-based biomaterials in tissue regeneration and engineering. Cytokine Growth Factor Rev 2022:S1359-6101(22)00039-9. [PMID: 35690567 DOI: 10.1016/j.cytogfr.2022.05.003] [Reference Citation Analysis]
14 Xu J, Lian W, Chen J, Li W, Li L, Huang Z. Chemical-defined medium supporting the expansion of human mesenchymal stem cells. Stem Cell Res Ther 2020;11:125. [PMID: 32192530 DOI: 10.1186/s13287-020-01641-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lee JY, Kang MH, Jang JE, Lee JE, Yang Y, Choi JY, Kang HS, Lee U, Choung JW, Jung H, Yoon YC, Jung KH, Hong SS, Yi EC, Park SG. Comparative analysis of mesenchymal stem cells cultivated in serum free media. Sci Rep 2022;12:8620. [PMID: 35597800 DOI: 10.1038/s41598-022-12467-z] [Reference Citation Analysis]
16 Seo Y, Kang MJ, Kim HS. Strategies to Potentiate Paracrine Therapeutic Efficacy of Mesenchymal Stem Cells in Inflammatory Diseases. Int J Mol Sci 2021;22:3397. [PMID: 33806241 DOI: 10.3390/ijms22073397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Li J, Luo M, Li B, Lou Y, Zhu Y, Bai X, Sun B, Lu X, Luo P. Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications. Front Immunol 2022;13:843192. [PMID: 35359961 DOI: 10.3389/fimmu.2022.843192] [Reference Citation Analysis]
18 Zhou HS, Cui Z, Wang H, Gao TT, Wang L, Wu J, Xiong ZY, Hao J, Zhao MH. The therapeutic effects of human embryonic stem cells-derived immunity-and-matrix regulatory cells on membranous nephropathy. Stem Cell Res Ther 2022;13:240. [PMID: 35672767 DOI: 10.1186/s13287-022-02917-w] [Reference Citation Analysis]